In contrast, echocardiographic measurements showed significantly higher EF (%) and FS (%) and shorter IVRT in AAV-SIRT5-treated DCM mice, and AAV-shGSTP1 administration resulted in a reduced therapeutic effect of AAV-SIRT5 (Fig. 6D-F). This evidence concerns the gene SIRT5 and familial dilated cardiomyopathy.